Aytu BioPharma FY2024 revenue $81M, adjusted EBITDA $9.2M; ADHD net revenue +23%

AYTU BIOPHARMA, INC

FY2024 consolidated net revenue $81.0M (down 25% YoY); net loss $15.8M ($2.86/share)
Adjusted EBITDA improved to $9.2M from $3.5M ( +162%); Rx Business EBITDA $10.8M
ADHD Portfolio net revenue +23% to $57.8M; Pediatric unit shipments up 115% since July 1
Consumer Health Segment divested in July 2024; company expects Rx Segment revenue and EBITDA growth in FY2025
Cash balance $20.0M; refinanced term loan; $3.5M from warrant exercises

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.